Latest News
Kedrion to be honoured at Premier's Supplier Innovation Celebration
7 October 2026 - Plasma-derived therapies company Kedrion Biopharma announced on Tuesday that it will be honoured by Premier Inc, a technology-driven healthcare improvement company, during the annual Supplier Innovation Celebration at its 2026 Breakt...
Enliven Therapeutics reaches FDA alignment on relcobatinib (ELVN-001) Phase 3 trial design for previously treated CML
7 October 2026 - Enliven Therapeutics Inc (Nasdaq:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, announced on Tuesday that it has reached alignment with the US Food and Drug ...
Accuray reports stockholder approval of financing-related proposals and appointment of independent director
7 October 2026 - Accuray Incorporated (Nasdaq:ARAY), a provider of radiation therapy accessories, announced on Tuesday that stockholders approved all proposals presented at the company's Special Meeting of Stockholders held on 6 October 2026, en...
Voyager signs cancer research mission management contract
6 October 2026 - Defence and space technology company Voyager Technologies (NYSE:VOYG) said on Tuesday that it has signed a contract with the Center for the Advancement of Science in Space to manage Symphony Biosciences' cancer research experime...
Orion Pharma to commercialise pembrolizumab biosimilar in Europe
6 October 2026 - Finnish pharmaceutical company Orion Corporation (Orion Pharma) (HEL:ORNBV) announced on Tuesday an agreement with Qilu Pharma Europe to commercialise Qilu's intravenous (IV) pembrolizumab biosimilar in Europe.Under the agreemen...